Skip to main content

Table 1 The demographic, clinical, and laboratory parameters of patients in both groups

From: The concentration of resistin in perivascular adipose tissue after CABG and postoperative atrial fibrillation

 

POAF group (n = 14)

No POAF group (n = 32)

P

Gender male N (%)

11 (78.6)

24 (75.0)

0.80

Age, years X ± SD

64.2 ± 6.3

67.5 ± 9.5

0.25

BMI, kg/m2 ± SD

28.6 ± 3.7

29.1 ± 4.5

0.72

Diabetes N (%)

2 (14.3)

16.0 (50)

0.02a

Hypertension N (%)

12 (85.7)

27 (84.4)

0.91

Previous myocardial infraction N (%)

5 (35.7)

10 (31.3)

0.77

Previous PCI N (%)

2 (14.3)

3 (9.4)

0.62

Stroke N (%)

2 (14.3)

0 (0)

0.18

Paroxysmal AF in history N (%)

4 (28.6)

0 (0)

0.01a

Waist, cm ± SD

100.5 ± 10.5

99.1 ± 10.3

0.68

GFR < 40, ml/min N (%)

3 (21.4)

0 (0)

0.05a

HbA1c, mmol/l ± SD

6.1 ± 0.6

6.3 ± 1.0

0.51

Glucose, mg% ± SD

113.2 ± 47.2

119.9 ± 45.8

0.66

Insulin, uU/mL ± SD

16.1 ± 8.6

24.2 ± 25.4

0.25

CHA2DS2VASc score ± SD

2.6 ± 1.4

2.9 ± 1.1

0.51

Betablockers N (%)

12 (85.7)

26 (68.4)

0.71

ACEI N (%)

9 (64.3)

15 (46.9)

0.28

Aortic cross clamp time, minutes±SD

40.5 ± 11.0

42.3 ± 10.6.

0.61

Cardiopulmonary bypass time, minutes±SD

78.4 ± 19.2

79.0 ± 17.2

0.92

COPD N (%)

0 (0)

1 (3.1)

0.67

Stenosis of RCA ≥ 90% N(%)

8 (57.1)

12 (37.5)

0.20

Potassium level, mEq/l ± SD

4.1 ± 0.4

4.2 ± 0.4

0.43

Magnesium level, mEq/l ± SD

2.1 ± 03

2,1 ± 0,3

0.93

  1. ACEI angiotensin-converting-enzyme inhibitor; AF atrial fibrillation; BMI body mass index; CHA2DS2VASc score for atrial fibrillation stroke risk calculator; COPD chronic obstructive pulmonary disease; GFR glomerular filtration rate; HbA1c glycated haemoglobin; POAF Postoperative atrial fibrillation; N number of patients, RCA right coronary artery; X mean value, SD standard deviation
  2. aStatistically significant